{
  "id": 7858283,
  "title": "Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy",
  "url": "https://urgent.news/2026/09/16/unprecedented-pfs-in-her2-mutant-lung-cancer-but-with-a-touch-of",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-16T18:45:01.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/iaslc/123021"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Progression-free survival (PFS) improved in advanced HER2-mutant non-small cell lung cancer (NSCLC) when treatment started with trastuzumab deruxtecan (T-DXd; Enhertu) instead of pembrolizumab (Keytruda) and chemotherapy, a large...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}